Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Level-Up: upadacitinib versus dupilumab in moderate to severe atopic dermatitis
MOH_2023-03-27_012479Phase 4Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in atopic dermatitis (AD) comparing Upadacitinib arm with Dupilumab arm (2 arms). Primary endpoints: Efficacy after 16 weeks of treatment and Safety. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
upadacitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2023-03-27_012479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-27_012479.